Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).
Patti F, Chisari CG, D'Amico E, Annovazzi P, Banfi P, Bergamaschi R, Clerici R, Conti MZ, Cortese A, Fantozzi R, Fischetti M, Frigo M, Gatto M, Immovilli P, Leoni S, Malucchi S, Maniscalco G, Marfia GA, Paolicelli D, Perini P, Serrati C, Sola P, Totaro R, Turano G, Valentino P, Zaffaroni M, Zuliani C, Centonze D. Patti F, et al. Among authors: gatto m. Mult Scler Relat Disord. 2020 Jul;42:102124. doi: 10.1016/j.msard.2020.102124. Epub 2020 Apr 13. Mult Scler Relat Disord. 2020. PMID: 32353755 Free article.
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Lepore V, et al. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. Eur J Neurol. 2021. PMID: 33058344
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group.. Chisari CG, et al. J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28. J Neurol. 2022. PMID: 34181077
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register. Paolicelli D, et al. Among authors: gatto m. J Neurol. 2019 Dec;266(12):3098-3107. doi: 10.1007/s00415-019-09531-6. Epub 2019 Sep 18. J Neurol. 2019. PMID: 31535270
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Amato MP, et al. Among authors: gatto m. Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. Brain. 2020. PMID: 32935843
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A; Italian MS registry. Baroncini D, et al. JAMA Neurol. 2021 Jun 1;78(6):726-735. doi: 10.1001/jamaneurol.2021.1008. JAMA Neurol. 2021. PMID: 33938921 Free PMC article.
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Brescia Morra V, Zaffaroni M, Pozzilli C, Cocco E, Sola P, Salemi G, Inglese M, Bergamaschi R, Gasperini C, Conte A, Salvetti M, Lus G, Maniscalco GT, Totaro R, Vianello M, Granella F, Ferraro E, Aguglia U, Gatto M, Sangalli F, Chisari CG, De Luca G, Carotenuto A, Baroncini D, Colombo D, Nica M, Paolicelli D, Comi G, Filippi M, Amato MP, Trojano M. Iaffaldano P, et al. Among authors: gatto m. Mult Scler. 2022 Dec;28(14):2243-2252. doi: 10.1177/13524585221114007. Epub 2022 Aug 15. Mult Scler. 2022. PMID: 35971322
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M; Italian MS Register. Ferraro D, et al. J Neurol. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Epub 2021 Jul 22. J Neurol. 2022. PMID: 34292396
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.
Bergamaschi R, Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Mosconi P; Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of Italian SM and Related Disorders Register; Aguglia U, Amato MP, Ancona AL, Ardito B, Avolio C, Balgera R, Banfi P, Barcella V, Barone P, Bellantonio P, Berardinelli A, Bergamaschi R, Bertora P, Bianchi M, Bramanti P, Morra VB, Brichetto G, Brioschi AM, Buccafusca M, Bucello S, Busillo V, Calchetti B, Cantello R, Capobianco M, Capone F, Capone L, Cargnelutti D, Carrozzi M, Cartechini E, Cavaletti G, Cavalla P, Celani MG, Clerici R, Clerico M, Cocco E, Confalonieri P, Coniglio MG, Conte A, Corea F, Cottone S, Crociani P, D'Andrea F, Danni MC, De Luca G, de Pascalis D, De Riz M, De Robertis F, De Rosa G, De Stefano N, Corte MD, Di Sapio A, Docimo R, Falcini M, Falcone N, Fermi S, Ferraro E, Ferrò MT, Fortunato M, Foschi M, Gajofatto A, Gallo A, Gallo P, Gatto M, Gazzola P, Giordano A, Granella F, Grasso MF, Grasso MG, Grimaldi LME, Iaffaldano P, Imperiale D, Inglese M, Iodice R, Leva S, Luezzi V, Lugaresi A, Lus G, Maimone D, Mancinelli L, Maniscalco GT, Marfia GA, Marini B, Marson A, Mascoli N, Ma… See abstract for full author list ➔ Bergamaschi R, et al. Among authors: gatto m. Neurol Sci. 2022 Sep;43(9):5459-5469. doi: 10.1007/s10072-022-06169-7. Epub 2022 Jun 7. Neurol Sci. 2022. PMID: 35672479 Free PMC article.
467 results